Contemporary reoperative mitral valve surgery: technical considerations and clinical outcomes

A Fatehi Hassanabad, M Turcotte, C Dennehy… - …, 2020 - journals.sagepub.com
As patients with cardiac disease live longer, reoperative mitral valve surgery has become
more common. Although these operations are technically challenging and of high risk …

Adverse events following transcatheter edge-to-edge repair (TEER) Using MitraClip: lessons learned from the Manufacturer and User Facility Device Experience …

SN Dodoo, AK Okoh, A Oseni, O Odiete… - Cardiovascular …, 2022 - Elsevier
Abstract Objective The MitraClip from Abbott is FDA approved intracardiac implantable
device for transcatheter edge-to-edge repair (TEER). Despite a few previously published …

Assessing the Reproducibility of Research Based on the Food and Drug Administration Manufacturer and User Facility Device Experience Data

X Li, Y Feng, Y Gong, Y Chen - Journal of Patient Safety, 2024 - journals.lww.com
Objective This article aims to assess the reproducibility of Manufacturer and User Facility
Device Experience (MAUDE) data-driven studies by analyzing the data queries used in their …

[HTML][HTML] Postdischarge-to-30-day mortality among patients receiving MitraClip: a systematic review and meta-analysis

BR Verma, S Shekhar, T Isogai, R Chava… - Structural Heart, 2022 - Elsevier
Background MitraClip (MC) implantation is the recommended treatment for severe
symptomatic mitral regurgitation in patients not responding to medical therapy and at …

[HTML][HTML] Standardised definitions of transcatheter edge-to-edge repair leaflet adverse events: identifying complications or complicating identification?: Standardised …

RT Hahn - EuroIntervention, 2021 - ncbi.nlm.nih.gov
Transcatheter edge-to-edge repair (TEER) is now a class IIa (1) or IIb (2) recommendation
for patients with high surgical risk and patients with severe primary mitral regurgitation (MR) …

Death Incidents Following Transcatheter Edge-to-Edge Repair (TEER) With the MitraClip Device: Analysis of 10-years Post-marketing Death Reports from the …

XH Sun, Y Zhao, Y Li - medRxiv, 2024 - medrxiv.org
Objective: The MitraClip device (Abbott), an FDA-approved transcatheter apparatus, is
employed for the management of mitral regurgitation (MR) among patients deemed at high …

Learning curve and procedural volume in mitral valve disease

M Saccocci, A Colli - Journal of Cardiac Surgery, 2021 - Wiley Online Library
The impact of procedural volume on outcome results is a widespread topic in surgery, The
importance of referral centers and high‐volume hospitals have reached the forefront …

Adjunctive use of fluoroscopy during MitraClip implantation reduces procedural complexity: The parallax technique

GD Singh, JH Rogers, S Chen, J Yap… - Catheterization and …, 2021 - Wiley Online Library
Abstract Background During MitraClip implantation sub‐valvular correction of trajectory
and/or alignment may increase adverse clip or leaflet events. With systematic adjunctive use …

Reply: Explaining differing outcomes from the COAPT and MITRA-FR trials using disproportionate and proportionate secondary mitral regurgitation

M Adamo, M Metra - EUROINTERVENTION, 2020 - eurointervention.pcronline.com
First, our results should not be considered in contrast to Grayburn's hypothesis. There are
two main explanations for the lack of differences in outcomes of patients with proportionate …

[HTML][HTML] MitraClip Insertion to Hasten Recovery from Severe COVID-19

V Nagaraja, TKM Wang, SC Harb, SR Kapadia - CASE, 2021 - Elsevier
Discussion The true impact of severe valvular heart disease in patients with COVID-19 has
not described in the literature so far. 3, 9, 10 Nevertheless, it is clear that patients with severe …